



August 06, 2025

The General Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

**COMPANY CODE : BAYERCROP**  
**SCRIP CODE : 506285**

Dear Sir / Madam,

**Sub.: Outcome of Board Meeting – August 06, 2025.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., August 06, 2025, has inter alia, approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2025. We attach a copy of the same along with the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

Further, please take a note that the Board Meeting commenced at 01:00 p.m. (IST) and concluded at 02:00 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,

*for* **Bayer CropScience Limited**

**Bharati Shetty**  
Company Secretary and Compliance Officer  
(Membership No.: ACS 24199)

Encl.: As above

Bayer CropScience Ltd.  
CIN: L24210MH1958PLC011173

Registered and Corporate Office:  
Bayer House  
Central Avenue  
Hiranandani Estate  
Thane (West) – 400 607  
Maharashtra, India

Tel : +91 22 2531 1234  
Fax : +91 22 2545 5063  
[www.bayer.in](http://www.bayer.in)  
[www.cropscience.bayer.com](http://www.cropscience.bayer.com)

**RESTRICTED**

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS  
TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of BAYER CROPSCIENCE LIMITED ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

MOHAMMED  
SAIFUDDIN  
BENGALI

Digitally signed by  
MOHAMMED  
SAIFUDDIN BENGALI  
Date: 2025.08.06  
14:08:06 +05'30'

Mohammed Bengali  
(Partner)  
Membership No. 105828  
(UDIN: 25105828BMMLVA6953)

Mumbai  
August 6, 2025

**BAYER CROPSCIENCE LIMITED**

**Registered Office:**

Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607  
CIN L24210MH1958PLC011173

<b>PART I</b>				₹ in Millions
<b>STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025</b>				
<b>PARTICULARS</b>	<b>Quarter Ended</b>			<b>Year Ended</b>
	<b>30.06.2025</b>	<b>31.03.2025</b>	<b>30.06.2024</b>	<b>31.03.2025</b>
	<b>UNAUDITED</b>	<b>UNAUDITED</b>	<b>UNAUDITED</b>	<b>AUDITED</b>
Revenue from Operations	19,146	10,464	16,314	54,734
Other Income	187	371	273	1,197
<b>Total Income</b>	<b>19,333</b>	<b>10,835</b>	<b>16,587</b>	<b>55,931</b>
<b>Expenses</b>				
Cost of Materials Consumed	10,395	9,790	8,458	35,864
Purchases of Stock-in-Trade	630	222	511	1,530
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	680	(4,371)	876	(3,406)
Employee Benefits Expense	1,043	1,112	996	4,498
Finance Costs	47	57	42	170
Depreciation and Amortisation Expense	272	343	215	849
Other Expenses	2,914	2,003	2,331	9,352
<b>Total Expenses</b>	<b>15,981</b>	<b>9,156</b>	<b>13,429</b>	<b>48,857</b>
<b>Profit Before Tax</b>	<b>3,352</b>	<b>1,679</b>	<b>3,158</b>	<b>7,074</b>
Tax Expense				
- Current Tax	580	350	604	1,514
- Deferred Tax	(15)	(104)	12	(120)
Total Tax Expense	565	246	616	1,394
<b>Profit for the period/ year</b>	<b>2,787</b>	<b>1,433</b>	<b>2,542</b>	<b>5,680</b>
<b>Other Comprehensive Income</b>				
Items that will not be reclassified to profit or loss:				
- Remeasurement of Defined Benefit Obligation	(6)	(55)	(3)	(69)
- Tax on remeasurement of Defined Benefit Obligation	2	13	1	17
<b>Total Other Comprehensive Income</b>	<b>(4)</b>	<b>(42)</b>	<b>(2)</b>	<b>(52)</b>
<b>Total Comprehensive Income for the period/ year</b>	<b>2,783</b>	<b>1,391</b>	<b>2,540</b>	<b>5,628</b>
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449
Reserves (excluding Revaluation Reserve as per Balance Sheet)				28,055
Earnings per share (basic and diluted) (*not annualised) in ₹	62.01*	31.88*	56.56*	126.38

**NOTES:**

1. The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.
2. The figures for the quarter ended March 31, 2025, are the balancing figures between audited figures for the financial year ended March 31, 2025 and the unaudited published year to date figures upto the third quarter of the previous financial year, which were subjected to limited review.
3. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 6, 2025. The above results have been subjected to limited review by the Statutory Auditors of the Company.

By Order of the Board



VINIT RAJESH  
JINDAL  
Digitally signed by VINIT RAJESH  
JINDAL  
Date: 2025.08.06 14:02:27 +05'30'

Vinit Jindal  
Executive Director and Chief Financial Officer  
DIN: 10849465

Place: Mumbai  
Date: August 6, 2025

Handwritten signature/initials